Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morpholine-4-Carboxylic Acid [1s-(2-Benzyloxy-1r-Cyano-Ethylcarbamoyl)-3-Methyl-Butyl]Amide is a synthetic small molecule belonging to the class of leucine derivatives and amides. It has a molecular formula of C21H30N4O4 and a molecular weight of approximately 402.5 g/mol. The compound is listed as an experimental drug, with no approved therapeutic indications or established mechanism of action reported in major chemical and pharmacological databases[1][2][3]. Its structure features a morpholine ring, benzyloxy group, cyano group, and methylated butyl side chain[3][4]. There is currently no information available regarding its clinical use, biological targets, or pharmacological activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on morpholine-4-carboxylic acid [1s-(2-benzyloxy-1r-cyano-ethylcarbamoyl)-3-methyl-butyl]amide.